Time of Metastatic Disease Presentation and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Prostate
Egile Nagusiak: Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Cristopher J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171350/
https://ncbi.nlm.nih.gov/pubmed/29707790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23645
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak